TITLE

Safety of fixed-dose aspirin--extended-release dipyridamole in patients with ischemic heart disease

AUTHOR(S)
Crown, Natalie; Mysak, Tania
PUB. DATE
May 2010
SOURCE
American Journal of Health-System Pharmacy;5/1/2010, Vol. 67 Issue 9, p728
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The safety of fixed-dose combination aspirin-extended-release (ER) dipyridamole for stroke prevention in patients with ischemic heart disease is reviewed. Summary. Randomized controlled trials have established the superiority of aspirin- ER dipyridamole over aspirin alone for secondary stroke prevention. One limitation of this product is the potential risk of worsening angina in patients with coronary artery disease. The English-language medical literature was searched for articles describing the cardiac safety of oral dipyridamole alone or in combination with aspirin. Metaanalyses, randomized controlled trials, observational studies, and case reports presenting information on the cardiac safety of oral dipyridamole were also reviewed. Four meta-analyses described vascular events with dipyridamole using various dosing strategies. Three trials included the endpoint of myocardial infarction in patients receiving ER dipyridamole. The meta-analyses and randomized controlled trials specifically evaluating aspirin-ER dipyridamole did not provide evidence of increased risk of vascular events. One post hoc analysis of a randomized controlled trial specifically assessed the cardiac safety of fixed-dose aspirin-ER dipyridamole and found that dipyridamole was not associated with a higher number of cardiac events compared with aspirin alone. One randomized controlled trial evaluated the efficacy of ER dipyridamole in patients with preexisting ischemic heart disease and found no evidence of increased risk of cardiac events in this population. No published reports were located describing angina with the combination product. Conclusion. A literature review revealed that fixed-dose aspirin-ER dipyridamole was not associated with an increased risk of cardiovascular events in patients with ischemic heart disease. However, individual patient factors merit consideration when choosing an antiplatelet agent for stroke prevention.
ACCESSION #
49443189

 

Related Articles

  • Asasantin Retard.  // Royal Society of Medicine: Medicines;2002, p88 

    The article presents information on Asasantin Retard, a proprietary, prescription-only compound preparation of the antiplatelet drugs dipyridamole and aspirin. It can be used to prevent thrombosis in the treatment of ischaemic stroke and ischaemic attacks. It is available in the form of capsules.

  • Aspirin related to the presence of cerebral microbleeds.  // Australian Journal of Pharmacy;Apr2010, Vol. 91 Issue 1079, p90 

    The article focuses on the association of the use of platelet aggregation inhibitors such as aspirin to cerebral microbleeds. Study shows no signification relation for anticoagulant drugs and the presence of microbleeds. It points out that the use carbasalate calcium and aspirin may be...

  • Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. Arnarsdottir, Lola; Hjalmarsson, Clara; Bokemark, Lena; Andersson, Bj”rn // BMC Neurology;2012, Vol. 12 Issue 1, p67 

    Background: Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these...

  • Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes. Hanna, Elias B.; Glancy, David Luke; Saucedo, Jorge F. // Cardiovascular Drugs & Therapy;Feb2010, Vol. 24 Issue 1, p61 

    The combination of aspirin and clopidogrel is the mainstay antiplatelet therapy for acute coronary syndromes (ACS). However, the dosing of aspirin, the dosing of clopidogrel, the timing of clopidogrel initiation as well as the duration of clopidogrel therapy remain controversial matters....

  • Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Warner, Timothy D.; Armstrong, Paul C. J.; Curzen, Nicholas P.; Mitchell, Jane A. // Heart;Nov2010, Vol. 96 Issue 21, p1693 

    Aspirin is now widely accepted as the first-line antithrombotic platelet therapy for at-risk individuals. During the last decade or so it has also become established that co-administering antagonists of the ADP receptor P2Y12 with aspirin further reduces the risk of acute thrombotic events. By...

  • Triple antiplatelet therapy after PCI with aspirin, clopidogrel and cilostazol. Wilczynska, Patrycja; Smith, Andrew J. // Cardiology Today;Feb2010, Vol. 13 Issue 2, p28 

    The article discusses several studies on the safety and efficacy of triple antiplatelet therapy following percutaneous coronary intervention (PCI) with aspirin, clopidogrel and cilostazol.

  • Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations. Karathanos, Athanasios; Geisler, Tobias // Molecular Diagnosis & Therapy;Jun2013, Vol. 17 Issue 3, p123 

    Antiplatelet therapy is the cornerstone of the treatment for patients with coronary artery disease (CAD). Dual therapy with clopidogrel and aspirin is currently the standard treatment after percutaneous coronary interventions. However, despite the use of clopidogrel, a considerable number of...

  • Untitled.  // PharmacoEconomics & Outcomes News;6/17/2006, Issue 505, p1 

    The article discusses research being done on the cost effectiveness of adding clopidogrel to aspirin in treating in-patients with ST-segment elevation myocardial infarction (STEMI). It references a study by Z. Zhang and colleagues in the May 30, 2006 online issue of the "Journal of the American...

  • Concurrent Antiplatelet and Fibrinolytic Therapy. Lange, Richard A.; Hillis, L. David // New England Journal of Medicine;3/24/2005, Vol. 352 Issue 12, p1248 

    Presents an editorial on concurrent antiplatelet and fibrinolytic therapy in patients with myocardial infarction. Combination of therapies which has been accepted in reducing mortality; How the medications work; Study in this issue on patients who were treated with fibrinolytic therapy and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics